Document is current
Any future updates will be listed below
-
Authors
Steffin, David
Ghatwai, Nisha
Montalbano, Antonino
Rathi, Purva
Courtney, Amy N.
Arnett, Azlann B.
Fleurence, Julien
Sweidan, Ramy
Wang, Tao https://orcid.org/0000-0003-1957-7160
Zhang, Huimin
Masand, Prakash
Maris, John M. https://orcid.org/0000-0002-8088-7929
Martinez, Daniel
Pogoriler, Jennifer
Varadarajan, Navin https://orcid.org/0000-0001-7524-8228
Thakkar, Sachin G.
Lyon, Deborah
Lapteva, Natalia
Zhuyong, Mei
Patel, Kalyani
Lopez-Terrada, Dolores
Ramos, Carlos A.
Lulla, Premal
Armaghany, Tannaz
Grilley, Bambi J.
Gottschalk, Stephen https://orcid.org/0000-0003-3991-7468
Dotti, Gianpietro
Metelitsa, Leonid S.
Heslop, Helen E. https://orcid.org/0000-0001-7049-7698
Brenner, Malcolm K.
Sumazin, Pavel
Heczey, Andras https://orcid.org/0000-0002-4263-9115
- License Information
-
More Information
Article History
Received: 14 March 2024
Accepted: 21 October 2024
First Online: 27 November 2024
Competing interests
: A.H., G.D., S.G. and L.S.M. have patents related to GPC3 CARs. A.H. is consultant for Waypoint Bio and serves on the Scientific Advisory Board of CARGO Therapeutics. A.H. has equity in CARGO. A.H. and L.S.M. received research support from Kuur/Athenex Therapeutics. A.H. and P.R. have a pending patent application related to cytokine co-expression in CAR T cells. N.V. is cofounder of CellChorus and AuraVax Therapeutics. M.K.B. has equity in AlloVir Inc., Marker Therapeutics, Tessa Therapeutics Ltd and March Biosciences, and serves on advisory boards for Marker Therapeutics, Allogene, Walking Fish, Abintus, Tessa Therapeutics, Athenex, Onk Therapeutics, Coya Therapeutics, Triumvira, Adaptimmune, Vor Therapeutics, Tscan, Kuur, Memgen and Turnstone Biologics Ltd. M.K.B. is the inventor of the iC9 safety switch. M.K.B. received royalties from Bellicum Pharmaceuticals. H.E.H. has equity in AlloVir Inc. and Marker Therapeutics and share options in CoRegen; has served on advisory boards for March Biosciences, Fresh Wind Biotechnologies, Kiadis, GSK, Marker Therapeutics and Tessa Therapeutics; and has received research support from Tessa Therapeutics and Kuur Therapeutics. S.G. is coinventor on patent applications in the fields of cell or gene therapy for cancer, and is a member of the Scientific Advisory Board of Be Biopharma and CARGO, and of the Data and Safety Monitoring Board of Immatics. B.J.G. owns QB Regulatory Consulting which has, or has had, agreements with Tessa Therapeutics, AlloVir (including equity), Marker Therapeutics, Lokon Pharma and March Biosciences. C.A.R. has participated in advisory boards for Novartis, Genentech and CRISPR Therapeutics, and has received research funding from Athenex and Tessa Therapeutics. P.L. served on the advisory board for Janssen Therapeutics and receives research funding from Marker Therapeutics. A.M. has equity in Immunai Inc. The other authors declare no competing interests. N.L. received research support from Tessa Therapeutics.
